» Articles » PMID: 36689040

Solanum Nigrum L. in COVID-19 and Post-COVID Complications: a Propitious Candidate

Overview
Publisher Springer
Specialty Biochemistry
Date 2023 Jan 23
PMID 36689040
Authors
Affiliations
Soon will be listed here.
Abstract

COVID-19 is caused by severe acute respiratory syndrome coronavirus-2, SARS-CoV-2. COVID-19 has changed the world scenario and caused mortality around the globe. Patients who recovered from COVID-19 have shown neurological, psychological, renal, cardiovascular, pulmonary, and hematological complications. In some patients, complications lasted more than 6 months. However, significantly less attention has been given to post-COVID complications. Currently available drugs are used to tackle the complications, but new interventions must address the problem. Phytochemicals from natural sources have been evaluated in recent times to cure or alleviate COVID-19 symptoms. An edible plant, Solanum nigrum, could be therapeutic in treating COVID-19 as the AYUSH ministry of India prescribes it during the pandemic. S. nigrum demonstrates anti-inflammatory, immunomodulatory, and antiviral action to treat the SARS-CoV-2 infection and its post-complications. Different parts of the plant represent a reduction in proinflammatory cytokines and prevent multi-organ failure by protecting various organs (liver, kidney, heart, neuro, and lung). The review proposes the possible role of the plant S. nigrum in managing the symptoms of COVID-19 and its post-COVID complications based on in silico docking and pharmacological studies. Further systematic and experimental studies are required to validate our hypothesis.

Citing Articles

Study on the apoptosis of human melanoma cells induced by solanine in vitro and its mechanisms.

Feng S, Ren M, Chen S, Wang B, Zhang Y, Zhang G Arch Dermatol Res. 2024; 317(1):163.

PMID: 39738917 DOI: 10.1007/s00403-024-03665-y.


Solamargine acts as an antiviral by interacting to MZF1 and targeting the core promoter of the hepatitis B virus gene.

Chen W, Zhao X, Huang Y, Lu K, Li Y, Li X Aging (Albany NY). 2024; 16(15):11668-11682.

PMID: 39133152 PMC: 11346786. DOI: 10.18632/aging.206047.

References
1.
Liu P, Ma Z, Deng Y, Li Y, Xia W, Liu Y . Characteristics and Effectiveness of the Coronavirus Disease 2019 (COVID-19) Prevention and Control in a Representative City in China. Med Sci Monit. 2020; 26:e927472. PMC: 7763915. DOI: 10.12659/MSM.927472. View

2.
Alsharif W, Qurashi A . Effectiveness of COVID-19 diagnosis and management tools: A review. Radiography (Lond). 2020; 27(2):682-687. PMC: 7505601. DOI: 10.1016/j.radi.2020.09.010. View

3.
Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis I . Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2020; 21(2):167-179. PMC: 7598940. DOI: 10.1007/s10238-020-00671-y. View

4.
Abdool Karim S, Abdool Karim Q . Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021; 398(10317):2126-2128. PMC: 8640673. DOI: 10.1016/S0140-6736(21)02758-6. View

5.
Umakanthan S, Sahu P, Ranade A, Bukelo M, Rao J, Abrahao-Machado L . Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020; 96(1142):753-758. PMC: 10016932. DOI: 10.1136/postgradmedj-2020-138234. View